22/04/2019 19:27:13

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Akorn, Inc.

LOS ANGELES, April 22, 2019 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the April 22, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Akorn, Inc. (“Akorn” or the “Company”) (NASDAQ: AKRX) securities between August 1, 2018 and January 8, 2019, inclusive (the “Class Period”). Akorn investors have until April 22, 2019 to file a lead plaintiff motion in this class action.

If you are a shareholder who suffered a loss, click here to participate.

If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com.

On January 9, 2019, Akorn announced that it had received a warning letter “dated January 4, from the U.S. Food and Drug Administration (FDA) related to an inspection of its Decatur, Illinois manufacturing facility in April and May of 2018.” The warning letter from the FDA detailed a laundry list of “significant violations of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals.” On this news, shares of Akorn fell $0.46 per share or over 11.6% to close at $3.48 per share on January 9, 2019, thereby injuring investors.

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Akorn’s management misled investors concerning the severity of Akorn’s manufacturing violations at its Decatur, Illinois facility; (2) Akorn’s responses to the FDA’s Form 483—which contained a list of observations made by the FDA during its inspection of Akorn’s Decatur, Illinois facility in April and May 2018—would be deemed inadequate by the FDA; (3) Akorn repeatedly failed to correct manufacturing violations at this facility; (4) the foregoing would subject Akorn to heightened regulatory scrutiny by the FDA; and (5) as a result, Akorn’s public statements were materially false and misleading at all relevant times.

Follow us for updates on Twitter: twitter.com/GPM_LLP.

If you purchased or otherwise acquired Akorn securities during the Class Period you may move the Court no later than April 22, 2019 to request appointment as lead plaintiff in this putative class action lawsuit. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com.  If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Glancy Prongay & Murray LLP, Los Angeles

Lesley Portnoy, 310-201-9150 or 888-773-9224

shareholders@glancylaw.com

www.glancylaw.com

GPM Logo.jpg

Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
10 Sep
DANSKE
Danske Bank får på børsen den 9. september 2019 endelig en god dag med en solid kursstigning. Det sk..
22
10 Sep
DANSKE
Igen ser vi håbløse Berlingske med en historie om at danske bank har skylden får at nogle har tabt p..
19
13 Sep
SAS-DKK
Tænk hvis det var en kvinde eller etnisk minoritet der var blevet mobbet og truet så var de skinhell..
17
12 Sep
 
Det nye Nordnet er uigennemskueligt, aktielisterne er uoverskuelige og generelt er platformens bruge..
16
12 Sep
CHEMM
Spørgsmålet er langt mere kompliceret end det lyder. Men Chemometec er en uendelig lille fisk i et m..
15
12 Sep
PNDORA
Forstår ikke en rygende fis af det indlæg. En der venligst vil oversætte?
13
13 Sep
BAVA
Årsagen er følgende: Indenfor 17 dage er Kopper 99% sikker godkendt samt de får et bevis til ca 100 ..
12
10 Sep
DANSKE
Du er jo ikke den eneste vælger i Danmark, der bare hader banker. Det har mange medier og politikker..
12
00:13
VELO
Velkommen til ugens faste tråd om Veloxis & Envarsus 😊   Det har været endnu en stille uge for Velo..
11
13 Sep
BAVA
Jeg må indrømme, at jeg har mere end svært ved at forstå, at så mange tvivler på godkendelse af kopp..
11

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Worldline: Information relating to the total number of voting rights and shares making up the share capital as at August 31, 2019
2
OTEGLOBE Doubles Subsea Network Capacity with Infinera Deployment
3
The Nomination Committee's proposal regarding Board of Directors and auditor of Oasmia Pharmaceutical AB for AGM 2019
4
Global Cloud Xchange Announces Plan to Secure Financial Future
5
AIR Worldwide Estimates Insured Losses for Typhoon Faxai Will be Between USD 3 Billion and USD 7 Billion

Latest news


Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
16 September 2019 10:05:16
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190829.2 - EUROWEB6 - 2019-09-16 11:05:16 - 2019-09-16 10:05:16 - 1000 - Website: OKAY